Owkin is a TechBio company that combines the best of human and artificial intelligence (AI) to ensure every patient gets the right treatment. By understanding complex biology through AI, it identifies new treatments, de-risks and accelerates clinical trials and develops AI diagnostics. Owkin uses privacy-enhancing federation to access up-to-date multimodal patient data that unlocks AI’s potential to power precision medicine. Owkin founded MOSAIC, a multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).